Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soignet, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soignet, S. L.
The Oncologist, Vol. 6, Suppl 2, 11-16, April 2001
© 2001 AlphaMed Press

SUPPLEMENT

Clinical Experience of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

Steven L. Soignet

Memorial Sloan-Kettering Cancer Center and Department of Medicine, and the Joan and Sanford Weill Medical College of Cornell University, New York, New York, USA

Correspondence: Steven L. Soignet, M.D., Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021-6007, USA. Telephone 212-639-8984; Fax 212-717-3172; e-mail: soignets{at}mskcc.org

Acute promyelocytic leukemia (APL) has unique clinical, cytogenetic, and molecular features and is one of the most potentially curable human malignancies. The current standard treatment given to patients with newly diagnosed APL con-sists of all-trans retinoic acid and anthracycline-based cytotoxic chemotherapy, which is highly effective for remission induction. However, despite the potential for cure with existing treatments, approximately 20%-30% of patients relapse and require salvage therapy. Reports of the safety and efficacy of arsenic trioxide from centers in China led to a pivotal trial of this agent in the United States for patients with relapsed APL. In an initial pilot study, 11 of 12 patients experienced a complete response, and a subsequent multicenter trial confirmed the efficacy and safety of arsenic trioxide for remission induction in this patient population. Additional trials are under way to evaluate the use of this agent alone or as part of a chemotherapy regimen for consolidation and maintenance of patients with APL.

Key Words. Acute promyelocytic leukemia • Arsenic trioxide • All-trans retinoic acid • Chemotherapy




This article has been cited by other articles:


Home page
 BloodHome page
A. A. Morales, D. Gutman, K. P. Lee, and L. H. Boise
BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma
Blood, May 15, 2008; 111(10): 5152 - 5162.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Peng, L. Peng, Y. Fan, E. Zandi, H. G. Shertzer, and Y. Xia
A Critical Role for I{kappa}B Kinase beta in Metallothionein-1 Expression and Protection against Arsenic Toxicity
J. Biol. Chem., July 20, 2007; 282(29): 21487 - 21496.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M.-T. Park, Y.-H. Kang, I.-C. Park, C.-H. Kim, Y.-S. Lee, H. Y. Chung, and S.-J. Lee
Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 82 - 92.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. McCollum, P. C. Keng, J. C. States, and M. J. McCabe Jr.
Arsenite Delays Progression through Each Cell Cycle Phase and Induces Apoptosis following G2/M Arrest in U937 Myeloid Leukemia Cells
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 877 - 887.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-H. Kang, M.-J. Yi, M.-J. Kim, M.-T. Park, S. Bae, C.-M. Kang, C.-K. Cho, I.-C. Park, M.-J. Park, C. H. Rhee, et al.
Caspase-Independent Cell Death by Arsenic Trioxide in Human Cervical Cancer Cells: Reactive Oxygen Species-Mediated Poly(ADP-ribose) Polymerase-1 Activation Signals Apoptosis-Inducing Factor Release from Mitochondria
Cancer Res., December 15, 2004; 64(24): 8960 - 8967.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
E. T.H. Yeh, A. T. Tong, D. J. Lenihan, S. W. Yusuf, J. Swafford, C. Champion, J.-B. Durand, H. Gibbs, A. A. Zafarmand, and M. S. Ewer
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Circulation, June 29, 2004; 109(25): 3122 - 3131.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Li, P. Chen, N. Sinogeeva, M. Gorospe, R. P. Wersto, F. J. Chrest, J. Barnes, and Y. Liu
Arsenic Trioxide Promotes Histone H3 Phosphoacetylation at the Chromatin of CASPASE-10 in Acute Promyelocytic Leukemia Cells
J. Biol. Chem., December 13, 2002; 277(51): 49504 - 49510.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.
Advertisement